Henry Schein (NASDAQ:HSIC)‘s stock had its “neutral” rating reaffirmed by JPMorgan Chase & Co. in a research report issued on Thursday. They currently have a $77.00 target price on the stock, down from their previous target price of $79.00. JPMorgan Chase & Co.’s price objective would suggest a potential upside of 12.52% from the stock’s previous close.

Several other brokerages also recently weighed in on HSIC. Zacks Investment Research downgraded Henry Schein from a “hold” rating to a “sell” rating in a research note on Monday, November 13th. Robert W. Baird set a $95.00 target price on Henry Schein and gave the company a “buy” rating in a research note on Thursday, October 19th. Stifel Nicolaus dropped their price objective on Henry Schein from $89.00 to $77.00 and set a “hold” rating on the stock in a research note on Tuesday, November 7th. Craig Hallum raised Henry Schein from a “hold” rating to a “buy” rating in a research note on Tuesday, November 7th. Finally, Evercore ISI assumed coverage on Henry Schein in a research note on Thursday, January 4th. They issued an “outperform” rating and a $81.00 price objective on the stock. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $83.71.

Shares of Henry Schein (NASDAQ HSIC) traded up $1.04 during trading on Thursday, reaching $68.43. The company’s stock had a trading volume of 2,571,500 shares, compared to its average volume of 2,005,261. The company has a quick ratio of 0.86, a current ratio of 1.55 and a debt-to-equity ratio of 0.30. The company has a market cap of $10,577.16, a P/E ratio of 19.47, a P/E/G ratio of 1.73 and a beta of 1.00. Henry Schein has a 52-week low of $63.01 and a 52-week high of $93.50.

In related news, Director Barry J. Alperin sold 5,796 shares of Henry Schein stock in a transaction on Friday, December 1st. The stock was sold at an average price of $70.76, for a total value of $410,124.96. Following the transaction, the director now directly owns 48,172 shares in the company, valued at approximately $3,408,650.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.19% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. grew its holdings in shares of Henry Schein by 0.8% in the 4th quarter. BlackRock Inc. now owns 11,752,750 shares of the company’s stock worth $821,284,000 after acquiring an additional 95,088 shares during the last quarter. Generation Investment Management LLP grew its holdings in shares of Henry Schein by 561.1% in the 4th quarter. Generation Investment Management LLP now owns 11,026,174 shares of the company’s stock worth $770,509,000 after acquiring an additional 9,358,345 shares during the last quarter. Mackenzie Financial Corp grew its holdings in shares of Henry Schein by 53.0% in the 4th quarter. Mackenzie Financial Corp now owns 6,023,557 shares of the company’s stock worth $420,926,000 after acquiring an additional 2,085,324 shares during the last quarter. Alecta Pensionsforsakring Omsesidigt grew its holdings in shares of Henry Schein by 112.0% in the 3rd quarter. Alecta Pensionsforsakring Omsesidigt now owns 5,313,980 shares of the company’s stock worth $435,693,000 after acquiring an additional 2,806,990 shares during the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of Henry Schein by 92.1% in the 3rd quarter. Janus Henderson Group PLC now owns 2,814,636 shares of the company’s stock worth $230,777,000 after acquiring an additional 1,349,333 shares during the last quarter. Institutional investors and hedge funds own 91.15% of the company’s stock.

WARNING: This piece was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://theolympiareport.com/2018/02/15/henry-schein-hsic-research-coverage-started-at-jpmorgan-chase-co.html.

About Henry Schein

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Analyst Recommendations for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.